Identification of long noncoding RNA
            <i>NEAT1</i>
            as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis

Chen, Ting; Sun, Zhengxu; Cui, Yunqi; Ji, Jiamei; Li, Yating; Qu, Xiaoyan

doi:10.1080/16078454.2022.2164449

Cited by 2 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it was not explained why only these specific 15 genes were selected for investigation. In a recent study, a microarray assay for long non-coding RNAs (lncRNAs) identified NEAT1 as highly expressed in EMD plasma cells and showed that it was associated with gain(1q21) [25]. NEAT1 can regulate gene transcription in key processes, including DNA repair and the cell cycle, and in this study, NEAT1 knockdown led to a reduction in the proliferation of in vitro myeloma cell lines [25].…”

Section: Altered Gene Expressionmentioning

confidence: 54%

Genetic Abnormalities in Extramedullary Multiple Myeloma

McAvera

Quinn

Murphy

et al. 2023

IJMS

View full text Add to dashboard Cite

Extramedullary multiple myeloma (or extramedullary disease, EMD) is an aggressive form of multiple myeloma (MM) that occurs when malignant plasma cells become independent of the bone marrow microenvironment. This may occur alongside MM diagnosis or in later stages of relapse and confers an extremely poor prognosis. In the era of novel agents and anti-myeloma therapies, the incidence of EMD is increasing, making this a more prevalent and challenging cohort of patients. Therefore, understanding the underlying mechanisms of bone marrow escape and EMD driver events is increasingly urgent. The role of genomics in MM has been studied extensively; however, much less is known about the genetic background of EMD. Recently there has been an increased focus on driver events for the establishment of distant EMD sites. Generally, high-risk cytogenetic abnormalities and gene signatures are associated with EMD, alongside mutations in RAS signalling pathways. More recently, changes in epigenetic regulation have also been documented, specifically the hypermethylation of DNA promoter regions. Therefore, the focus of this review is to summarize and discuss what is currently known about the genetic background of EMD in MM.

show abstract

Section: Altered Gene Expressionmentioning

confidence: 54%

Genetic Abnormalities in Extramedullary Multiple Myeloma

McAvera

Quinn

Murphy

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…We and others have shown the importance of lncRNAs in chromatin remodelling and the impact they have on MM patient outcome ( 6 , 15 – 17 ). In fact, aberrant lncRNA expression has been demonstrated to have an oncogenic role in MM pathogenesis and progression ( 35 , 36 ).…”

Section: Introductionmentioning

confidence: 93%

“…as, N6-methyladenosine (m6A), N1-methyladenosine (m1A), 5methylcytosine (m5C), and 7-methylguanosine (m7G), play a crucial role in regulating various aspects of lncRNA function, structure, stability, localization, and lncRNA-mediated interactions (26-34) (Figure 2). We and others have shown the importance of lncRNAs in chromatin remodelling and the impact they have on MM patient outcome (6,(15)(16)(17). In fact, aberrant lncRNA expression has been demonstrated to have an oncogenic role in MM pathogenesis and progression (35,36).…”

Section: Introductionmentioning

confidence: 99%

“…Prior studies, by us and others, have suggested that the epigenetic machinery plays a crucial role in MM pathogenesis, including aberrant DNA methylation and abnormal histone modification patterns (6)(7)(8)(9)(10)(11)(12)(13)(14). Furthermore, more recently, dysregulation of long non-protein coding RNAs (lncRNAs) has been suggested to contribute to MM pathogenesis, patient outcome and drug resistance (15)(16)(17). Additionally, dysregulation of lncRNAs has been shown to contribute to disease progression by influencing critical pathways involved in proliferation, apoptosis, immune response, and drug resistance (18,19).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma

Nylund,

Garrido-Zabala,

Kalushkova

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Extensive genome-wide sequencing efforts have unveiled the intricate regulatory potential of long non-protein coding RNAs (lncRNAs) within the domain of haematological malignancies. Notably, lncRNAs have been found to directly modulate chromatin architecture, thereby impacting gene expression and disease progression by interacting with DNA, RNA, and proteins in a tissue- or condition-specific manner. Furthermore, recent studies have highlighted the intricate epigenetic control of lncRNAs in cancer. Consequently, this provides a rationale to explore the possibility of therapeutically targeting lncRNAs themselves or the epigenetic mechanisms that govern their activity. Within the scope of this review, we will assess the current state of knowledge regarding the epigenetic regulation of lncRNAs and how, in turn, lncRNAs contribute to chromatin remodelling in the context of multiple myeloma.

show abstract

Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis

Cited by 2 publications

References 29 publications

Genetic Abnormalities in Extramedullary Multiple Myeloma

Genetic Abnormalities in Extramedullary Multiple Myeloma

The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma

Contact Info

Product

Resources

About